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DEP domain-containing mTOR-interacting protein
(DEPTOR) inhibits the mechanistic target of rapamy-
cin (mTOR), but its in vivo functions are unknown.
Previous work indicates that Deptor is part of
the Fob3a quantitative trait locus (QTL) linked to
obesity/leanness in mice, with Deptor expression
beingelevated inwhite adipose tissue (WAT)of obese
animals. This relation is unexpected, considering
the positive role of mTOR in adipogenesis. Here,
we dissected the Fob3a QTL and show that Deptor
is the highest-priority candidate promoting WAT
expansion in this model. Consistently, transgenic
mice overexpressing DEPTOR accumulate more
WAT. Furthermore, in humans, DEPTOR expression
in WAT correlates with the degree of obesity. We
show that DEPTOR is induced by glucocorticoids
during adipogenesis and that its overexpression
promotes, while its suppression blocks, adipogene-
sis. DEPTOR activates the proadipogenic Akt/PKB-
PPAR-g axis by dampening mTORC1-mediated
feedback inhibition of insulin signaling. These results
establish DEPTOR as a new regulator of adipo-
genesis.
INTRODUCTION
Obesity, which is defined by excessive white adipose tissue
(WAT) accumulation, increases mortality and the risk of devel-
oping multiple disorders including insulin resistance, type 2 dia-
betes, cardiovascular diseases, and cancers (Flegal et al., 2003,
2007; Pischon et al., 2008; Wang et al., 2005). Although changes
in lifestyle are responsible for the increase in incidence of obesity
over the last decades, heritability studies provide evidence for a
substantial genetic contribution to obesity risk (Bouchard et al.,
1990; Maes et al., 1997). Because strategies aiming to reduce
obesity have shown limited long-term success, an improvement202 Cell Metabolism 16, 202–212, August 8, 2012 ª2012 Elsevier Incin our understanding of the molecular mechanisms regulating
WAT formation is important for the development of new tools
to treat obesity and its related diseases.
The mTOR signaling pathway senses growth factors and
nutrients to regulate many biological processes involved in the
promotion of cell growth (Laplante and Sabatini, 2012). mTOR
interacts with several proteins to form two distinct multipro-
tein complexes named mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2). When active, mTORC1 promotes protein
synthesis by phosphorylating the eukaryotic initiation factor 4E
(eIF4E)-binding protein1 (4E-BP1) and the ribosomal S6 kinase
1 (S6K1), whereas mTORC2 regulates cell survival through the
phosporylation of several AGC kinases. It is becoming increas-
ingly clear that, in addition to protein synthesis, mTORC1 also
regulates lipid metabolism and adipogenesis (Laplante and Sa-
batini, 2009). Overactivation ofmTORC1 increases adipogenesis
in vitro (Zhang et al., 2009), whereas the complete inhibition of
mTORC1 by rapamycin or loss of RAPTOR, a keymTORC1 com-
ponent, blocks this process (Cho et al., 2004; Gagnon et al.,
2001; Kim and Chen, 2004; Polak et al., 2008; Yu et al., 2008;
Zhang et al., 2009). For these reasons, targeting mTORC1 sig-
naling represents a potential approach for reducing adiposity
and improving obesity-related diseases.
Recently, we identified the DEP domain-containing mTOR-in-
teracting protein (DEPTOR, also known as DEPDC6) as a protein
that represses mTOR signaling (Peterson et al., 2009). DEPTOR
interacts with mTORC1 and mTORC2, and its protein stability is
reduced when these complexes are active. We observed that
DEPTOR is low in most cancer cells but is surprisingly highly ex-
pressed in multiple myeloma (Peterson et al., 2009). In these
cells, high DEPTOR expression reduces mTORC1 activity and
S6K1-mediated feedback inhibition of phosphoinositide-3
kinase (PI3K), which contributes to the activation of protein
kinase B (Akt/PKB) and cell survival.
The role of DEPTOR in the regulation of physiological pro-
cesses in vivo is unknown. Before the identification of DEPTOR
as an mTOR-interacting protein, a section on chromosome 15
that includes the Deptor gene was identified as part of the
Fob3a quantitative trait locus (QTL) that is linked to obesity/lean-
ness in mice (Stylianou et al., 2005). It was reported that Deptor
expression is elevated in the adipose tissues of the mouse line.
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time focused on other candidate genes, the potential role of
Deptor in regulating fat accumulation was not examined.
The possibility that Deptor could favor adiposity is counterin-
tuitive, considering thewell-established positive role ofmTORC1
in regulating adipogenesis and adipose cell maintenance (Cho
et al., 2004; Gagnon et al., 2001; Kim and Chen, 2004; Polak
et al., 2008; Yu et al., 2008; Zhang et al., 2009). However,
because DEPTOR impairs mTORC1 action to a much lower
degree than rapamycin or RAPTOR loss, its impact on the regu-
lation of adipogenesis and WAT accumulation may be different.
Here, we used several congenic lines for dissecting the Fob3a
QTL and confirmed thatDeptor is a high-priority candidate regu-
lating WAT accumulation in the polygenic mouse model of
obesity/leanness. To demonstrate the positive role of Deptor
in regulating adiposity, we generated a doxycycline-inducible
transgenic mouse model for Deptor overexpression and found
that Deptor promotes WAT expansion. Consistent with these
observations, we noted that DEPTOR expression is elevated in
WAT of obese humans and positively correlates with the degree
of obesity. DEPTOR is induced during adipogenesis through
a glucocorticoid receptor (GR)-dependent mechanism, and its
expression facilitates adipocyte differentiation in a cell-autono-
mous fashion. We observe that DEPTOR positively regulates
adipogenesis by promoting the activity of the proadipogenic fac-
tors Akt/PKB and peroxisome proliferator-activated receptor-g
(PPAR-g). These results establish DEPTOR as a new physiolog-
ical regulator of adipogenesis.
RESULTS
Deptor Is a Strong Candidate Gene for Causing WAT
Accumulation in a Murine Polygenic Model of Obesity/
Leanness
A polygenic mouse model of obesity was previously developed
by divergent selective breeding and resulted in strains differing
substantially in fat content (Horvat et al., 2000; Sharp et al.,
1984). The mice were selected for high fat (Fat line) or low fat
(Lean line) content from a genetically highly variable base popu-
lation for more than 60 generations (Sharp et al., 1984), resulting
in lines that differ in body fat content by more than 5-fold. The
Fob3 QTL is one of several chromosomal regions controlling
obesity in the Fat and Lean mouse lines. The Fob3 region has
been dissected into distinct obesity QTLs called Fob3a,
Fob3b1, and Fob3b2 (Prevorsek et al., 2010; Stylianou et al.,
2005). Genetic mapping and microarray studies showed that
that Deptor, together with many other genes, is part of the
Fob3a QTL and could be involved in regulating adiposity (Stylia-
nou et al., 2004, 2005).
To examine the contribution of the Deptor-containing Fob3a
segment in the regulation of fat accumulation in the Fat mouse
strains, the Fob3a interval was genetically dissected by ana-
lyzing the phenotypes of several congenic lines (P, V, W, and Z)
with overlapping Fob3a regions of various lengths (Figure 1A).
Congenic lines P and Z carrying the Fat-line-derived Fob3a-Dep-
tor region had significantly increased weights of WAT compared
to lines V and W, which carry the Fob3a-Deptor region from the
Lean line (Figure 1B, left panel). These results were confirmed in
independent F2 congenic intercrosses (Figure 1B, middle andCelright panels) and were not dependent on changes in food intake
(see Figure S1A online). A cross-section analysis of overlapping
congenic segments fine mapped the Fob3a region down to an
15 Mbp region containing the Deptor gene (Figure 1C).
To further narrow down the genetic interval likely to con-
tain causal Fob3a QTL polymorphism(s), we performed Fob3a-
interval-specific haplotype analysis that identified genomic
blocks which are not identical by descent (non-IBD). Two non-
IBD regions within the Fob3a segment were identified (Fig-
ure 1C). Of the 29 genes included in this region, 22 genes were
considered as potential candidates (see the Experimental Proce-
dures). Strikingly,Deptorwas highly expressed inWAT of the Fat
line (8.9 fold, p < 0.001) and in the congenic line Z (8.3 fold, p <
0.001) carrying the Fob3a-Deptor segment derived from the
Fat line compared to the line V carrying the Fob3a-Deptor
segment derived from the Lean line (Figure 1D).Deptorwas simi-
larly regulated in the liver (Figure 1E). Microarray analyses also
confirmed the differential regulation of Deptor in WAT of an inde-
pendent F2 congenic intercross (Table S1). No other candidate
gene showed such a consistent differential regulation between
the lean and obese lines (Figures S1B–S1D and Table S1). In
order to narrow down the list of potential candidate genes,
we looked at the function (GO profile), the tissue distribution
(BioGPS), and the available transgenic/knockout data for all
the candidate genes included in the Fob3a region (see the Exper-
imental Procedures). Together with the expression results, these
analyses revealed that Deptor is the highest priority candidate
gene regulating fat accumulation in this model (Figure 1F and
Table S2).
Deptor Overexpression Promotes WAT Expansion
in Mice
To test the hypothesis that upregulation of Deptor plays a causal
role in obesity, we generated a doxycycline-inducible DEPTOR
transgenic mouse model (Figure 2A). For ease, we refer to this
model as iDeptor mice. This transgenic approach was selected
because it allowed a modest overexpression of DEPTOR in
many tissues, including WAT (Figure 2B, Figure S2A), thus
grossly mimicking the differences observed between the Lean
and Fat congenic mouse lines. iDeptor mice treated with doxy-
cycline did not show changes in body weight, body weight
gain, or tissue weight compared to control mice (Figures S2B
and S2C). When fed a high-fat diet containing doxycycline,
iDeptor mice gained more weight than controls (Figure 2C).
The increase in body weight in iDeptor mice was not caused
by changes in food intake or locomotion, but it was associated
with an increase in food efficiency (Figures S2D–S2F). The
weights of WAT and liver were significantly increased in iDeptor
mice (Figure 2D). Histological analyses revealed that, despite the
increase in WAT weight, DEPTOR expression did not change
average adipocyte size (Figures S2G and S2H), indicating that
DEPTOR affected WAT mass at least by increasing the number
of fat cells. Consistent with the increase in WAT mass, plasma
leptin was increased in iDeptor mice (Figure S2I). Lipid accu-
mulation in the liver, a condition known as hepatosteatosis,
was also increased by DEPTOR overexpression (Figures S2J
and S2K).
In order to evaluate if DEPTORmodulates the ability of WAT to
accumulate lipids, the expression of numerous genes encodingl Metabolism 16, 202–212, August 8, 2012 ª2012 Elsevier Inc. 203
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Figure 1. Deptor Gene Is Associated with Fat Accumulation in a Polygenic Model of Obesity/Leanness in Mice
(A) Genetic map of Fob3aQTL region on chromosome 15 based on congenic mapping analysis. Thick black box indicates the genome segment from the Fat line,
the white box indicates the genome segment from the Lean line, and the gray box indicates the region with uncertain origin.
(B) Effect of Deptor-containing Fob3a QTL region on WAT accumulation in homozygous congenic lines (left) and F2 congenic intercrosses (middle and right).
Data are presented as the mean of WAT mass for each mouse line. Lines with thick and thin vertical lines represent genotype estimates and 50% and 95%
confidence intervals. From the left panel, Fat line (n = 75) and lines P (n = 20), V (n = 32), W (n = 27), and Z (n = 37) were phenotyped. From the middle and right
panels, theWAT phenotype was re-evaluated in independent F2 populations. Mice were generated by crossing parental Fat line with congenic V (center panel) or
P (right panel) line, intercrossing the F1 generation and phenotyping the three F2 genotypes (n = 79 for the line V intercross and n = 45 for the line P intercross).
Asterisk denotes significance (p < 0.01) of the difference in WAT between the congenic line and the Fat line as well as the difference between genotypes in F2
congenic intercrosses.
(C) High-resolution map of the reduced Fob3a interval. The position of potential candidates is shown on the map, and corresponding interval size and number of
genes are indicated on the right side.
(D and E) DeptormRNA was measured by qRT-PCR in (D) WAT or in the (E) liver of the mouse lines and normalized to 36B4mRNA levels. Data are expressed as
the mean ± SEM for n = 8–12. *p < 0.05.
(F) Analysis of the bioinformatics and expression hits for the candidate genes included in the Fob3a interval. Hits were established as described in the Exper-
imental Procedures. The red square indicates a positive/possible role of the gene in the fat phenotype (hit), the gray square indicates no apparent relation with the
phenotype (no hit), and the white square indicates that data are not available.
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DEPTOR Regulates Adipogenesisproteins regulating lipogenesis and lipid uptake/retention was
measured in WAT of iDeptor mice. DEPTOR overexpression
significantly increased the mRNA levels of many of these
genes (Figure 2E). Interestingly, most of the genes increased
by DEPTOR have been previously identified as targets of the
master regulator of adipogenesis, PPAR-g (Berger and Moller,
2002; Guan et al., 2002; Nishino et al., 2008). These results indi-
cate that DEPTOR promotes WAT expansion at least in part by
improving the ability of this tissue to synthesize and accumulate
lipids. Importantly, DEPTOR overexpression also induced the
transcription of many lipogenic genes in the liver, which likely
contributed to promote hepatic triglyceride accumulation and
weight gain in iDeptor mice (Figure S2L).204 Cell Metabolism 16, 202–212, August 8, 2012 ª2012 Elsevier IncDEPTOR Levels Are Elevated in WAT of Obese Humans
Because DEPTOR overexpression promotes adiposity and the
expression of genes facilitating lipid accumulation in mice, we
asked if DEPTOR expression might also be associated with
obesity in humans. DEPTOR protein levels were measured in
WAT of humans with body mass indexes (BMIs) ranging from
22 to 80. Strikingly, DEPTOR protein expression was strongly
elevated in obese humans (3.47-fold in BMI >30, p = 0.0001)
(Figures 3A and 3B). Additionally, we noted a significant correla-
tion between DEPTOR protein levels and BMI (r = 0.42, p <
0.005). Importantly, no such correlation was observed with the
expression of other proteins, such as aP2 or Akt/PKB (Figures
S3A and S3B). Together with the results obtained in the mouse.
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Figure 2. DEPTOR Overexpression Promotes Adiposity in Mice
(A) Schematic representation of the strategy used to produce the iDeptor mouse model.
(B) iDeptor mice were euthanized, and tissues were collected 6 hr after PBS or doxycycline injection (3.3 mg/g body weight). Protein lysates were analyzed by
immunoblotting for indicated proteins.
(C and D) (C) Body and (D) tissue weight of control or iDeptor mice fed a high-fat diet supplemented with doxycycline (200 mg/kg food) for 6–7 weeks. Data are
expressed as the mean ± SEM for n = 6–8 per condition. *p < 0.05 versus control.
(E) Gene expression analysis in WAT of control and iDeptor mice fed a high-fat diet supplemented with doxycycline (200 mg/kg food) for 6–7 weeks. mRNA
expression was measured by qRT-PCR and normalized to 36B4mRNA levels. Data are expressed as the mean ± SEM for n = 5–8 per condition. *p < 0.05 versus
control.
Cell Metabolism
DEPTOR Regulates Adipogenesismodels, these observations support the possibility that DEPTOR
could play an important role in regulating WAT expansion in
humans.
DEPTOR Is Induced during WAT Development and
Adipocyte Differentiation
In order to better understand the biological function of DEPTOR
in adipose tissue/adipocytes, we examined if DEPTOR is regu-
lated during fat cell formation in vivo and in vitro. In WAT
collected from murine embryos and pups at different stages of
development, DEPTOR levels increased significantly during the
WAT formation that occurs asmice begin to suckle and accumu-
late fat (Figure 4A and Figure S4A). Consistent with these results,
DEPTOR levels also increased in mouse embryonic fibroblasts
(MEFs) and 3T3-L1 cells treated with an adipogenic cocktail
that promotes their differentiation into the mature adipocytes
(Figures 4B and 4C and Figure S4B). Thus, in vivo and in two
well-established in vitro models, DEPTOR expression increases
during adipogenesis.
We next took advantage of the in vitro adipogenesis systems
to investigate the mechanisms that regulate DEPTOR expres-
sion. Each component of the adipogenic cocktail was removed
individually, and DEPTOR levels were measured after the in-
duction of adipogenesis. Only the removal of dexamethasone,
a synthetic glucocorticoid, blocked the induction of DEPTOR
that occurs during differentiation (Figure 4D and Figure S4C).
The addition of dexamethasone or corticosterone increased
DEPTOR levels even in undifferentiated MEFs (Figures 4E–4G)
or 3T3-L1 cells (Figure S4D). Analyses of publicly available tran-Celscriptional profiling data showed that glucocorticoids induce
Deptor mRNA levels in mouse primary chondrocytes in vitro
and in the placenta in vivo, indicating that this mechanism of
regulation is conserved in various conditions and cell types
(Figures S4E and S4F). We observed that inhibition of transcrip-
tion by actinomycin D or of the GR by RU-486 completely abro-
gated the dexamethasone-induced increases in Deptor mRNA
and DEPTOR protein (Figure 4H). These results are consis-
tent with glucocorticoids directly controlling Deptor expression
through a transcriptional mechanism that depends on the GR.
Bioinformatics analyses revealed the presence of a conserved
glucocorticoid response element (GRE) in mouse and human
Deptor promoter (Figure 4I). In order to demonstrate a physical
interaction between the GR and theDeptor promoter, we treated
MEFs with dexamethasone and performed chromatin immuno-
precipitations (ChIPs) using an antibody against the GR. Using
this approach, we observed that dexamethasone promotes GR
binding to the Deptor promoter (Figure 4J). Importantly, binding
of GR to the Deptor promoter was enriched when the PCR was
performed close to the potential GRE, which supports the possi-
bility that this specific site may play a role in the control ofDeptor
expression by glucocorticoids.
An important question arising from this last set of results
relates to the temporal regulation of DEPTOR by glucocorticoids
during adipogenesis. If glucocorticoid signaling is an important
regulator of DEPTOR expression during adipogenesis, why is
the increase in DEPTOR levels relatively weak during the first
2 days of differentiation (Figure 4B)? Because in undifferentiated
MEFs dexamethasone induced DEPTOR expression within 5 hrl Metabolism 16, 202–212, August 8, 2012 ª2012 Elsevier Inc. 205
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Figure 3. DEPTOR Expression Is Elevated in WAT of Obese Humans
(A) Impact of BMI on DEPTOR protein expression in WAT. Protein lysates were
prepared from subcutaneous WAT isolated from lean and obese humans.
Lysates were then analyzed by immunoblotting for DEPTOR and b-ACTIN.
DEPTOR protein levels were quantified and normalized to b-ACTIN levels.
n = 16 (BMI < 30) and n = 39 (BMI >30), *p < 0.05 versus BMI < 30.
(B) Representative samples from the western blots are shown.
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nent of the adipogenic cocktail might counteract the positive
effects of dexamethasone on DEPTOR expression at early
time points. Indeed, we observed that IBMX dose-dependently
blocked the stimulatory effect of dexamethasone on DEPTOR
protein and Deptor mRNA levels (Figure S4G). Consistent with
this observation, IBMX removal from the adipogenic cocktail
promotedDeptormRNAexpression (Figure S4C). As a nonselec-
tive phosphodiesterase inhibitor, IBMX is thought to exert some
of its effects by raising intracellular cAMP levels. Treating cells
with various doses of the cAMP analog dibutyryl-cAMP or with
the adenylate cyclase activator forskolin did not reduce Deptor
expression in response to dexamethasone (data not shown),
indicating that IBMX competes with dexamethasone for the
control of Deptor expression by a mechanism that does not
depend on variation in cAMP levels.
DEPTOR Promotes Adipogenesis in a Cell-Autonomous
Fashion
To better understand the role of DEPTOR in adipogenesis, MEFs
isolated from iDeptor mice were treated or not with doxycycline
and were differentiated into mature adipocytes. Consistent
with the in vivo findings, DEPTOR overexpression significantly
increased triglyceride accumulation in MEFs (Figure 5A and
Figure S5A). Moreover, we noted a dose-dependent effect of
DEPTOR on the promotion of adipogenesis in this model (Fig-
ure S5B). Importantly, doxycycline per se had no effect on adipo-
cyte differentiation in wild-type MEFs (Figure S5C). Similar to
what was observed in WAT in vivo, DEPTOR overexpression
induced the expression of many genes regulated by PPAR-g
(Figures 5B and 5C and Figures S5D–S5F). In order to determine
which step in the adipogenic program is affected by DEPTOR
overexpression (commitment versus terminal differentiation),
DEPTOR was expressed in iDeptor MEFs during the early (day
2 to day +2) or the late (day +4 to day +12) stage of adipogen-
esis. Both treatments led to a significant increase in triglyceride
accumulation, indicating that DEPTOR expression triggers fat
cell development by promoting preadipocyte commitment as
well as lipid synthesis in committed cells (Figures 5D and 5E).
We next determined if DEPTOR expression is necessary for
adipocyte differentiation in vitro. Using 3T3-L1 cells, we ob-
served that suppression of DEPTOR expression by short-hairpin
RNA (shRNA) significantly reduced adipogenesis (Figure 5F and206 Cell Metabolism 16, 202–212, August 8, 2012 ª2012 Elsevier IncFigure S5G). This was associated with a reduction in PPAR-g
protein levels and mRNA expression of genes controlled by
PPAR-g (Figures 5G–5I and Figure S5H). Together, these results
indicate that DEPTOR controls adipogenesis in a cell-autono-
mous fashion by modulating the expression of PPAR-g and its
target genes.
DEPTOR Promotes Adipogenesis by Activating Akt/PKB
and PPAR-g
To better understand the mechanism by which DEPTOR
promotes adipogenesis, we examined the effect of DEPTOR
expression or depletion on mTOR signaling. Overexpression
of DEPTOR in MEFs reduced the phosphorylation of insulin
receptor substrate 1 (IRS1) at S636/639, a site directly targeted
by mTORC1 that favors IRS1 degradation (Tzatsos, 2009; Tzat-
sos and Kandror, 2006), and promoted the phosphorylation/
activation of Akt/PKB (Figure 6A). We also observed that dexa-
methasone and corticosterone, which both promote DEPTOR
expression, also induced Akt/PKB phosphorylation in MEFs
(Figures S6A and S6B). Moreover, the induction of DEPTOR ex-
pression during adipogenesis was associated with an increase
in Akt/PKB activation (Figures S6C and S6D). Such an elevation
in Akt/PKB phosphorylation was also observed in adipose tis-
sue of mice overexpressing DEPTOR (Figure S6E). Conversely,
suppression of DEPTOR expression in 3T3-L1 cells increased
IRS1 phosphorylation at S636/639, reduced IRS1 levels, and
blocked Akt/PKB activation (Figure 6B). DEPTOR depletion
also reduced Akt/PKB-mediated Forkhead box O1/3a (FoxO1/
3a) phosphorylation and nuclear exclusion (Figure S6F). Impor-
tantly, Akt/PKB activation was impaired in DEPTOR-depleted
3T3-L1 cells treated with insulin-like growth factor-1 (IGF-1), a
keymoleculepromotingpreadipocytedifferentiation (FigureS6G)
(Smith et al., 1988). We also noted a significant reduction in Akt/
PKB activation over the differentiation process in DEPTOR-
depleted 3T3-L1 cells (Figure S6H).
It was reported that the complete inhibition of mTORC1 blocks
WAT accumulation in vivo and adipogenesis in vitro (Cho et al.,
2004; Gagnon et al., 2001; Kim and Chen, 2004; Polak et al.,
2008; Yu et al., 2008; Zhang et al., 2009). Because DEPTOR
inhibits mTORC1 (Peterson et al., 2009), it might be expected
that DEPTOR expression would repress lipid accumulation in
adipocytes. Importantly, although DEPTOR had a significant
impact on the phosphorylation of IRS1 S636/639, we noted
that the activation state of other classic downstream effectors
of mTORC1 (S6K1, S6, or 4E-BP1) was not severely affected
by the overexpression/knockdown of DEPTOR (Figures 6A and
6B). This indicates that DEPTOR does not impair mTORC1
activity to the same extent as rapamycin or RAPTOR loss,
which probably explains why DEPTOR does not similarly affect
adipogenesis.
Adipogenesis is a cellular process that requires the activation
of Akt/PKB (Kohn et al., 1996;Magun et al., 1996;Menghini et al.,
2005; Nakae et al., 2003; Peng et al., 2003). Akt/PKB induces
glucose uptake, its metabolism, and its incorporation into lipids
and promotes the activation of PPAR-g through various mecha-
nisms (Rosen and MacDougald, 2006). Because DEPTOR posi-
tively regulates Akt/PKB and the expression of many genes
downstream of PPAR-g, we tested the possibility that DEPTOR
could affect adipogenesis by modulating the Akt/PKB-PPAR-g.
Cell Metabolism
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uptake and lipogenesis, we observed that modulation in Akt/
PKB activation by DEPTOR was associated with significant
changes in glucose uptake and incorporation into lipids (Fig-
ure 6C and Figure S6I). Importantly, we also observed that
expression of a constitutively active Akt/PKB corrected the
adipogenic defect observed when DEPTOR was depleted, indi-
cating that DEPTOR affects adipogenesis upstream of Akt/PKB
(Figure 6D). Because Akt/PKB is a strong activator of PPAR-g,
we also looked at the impact of DEPTOR on the activity of this
transcription factor. DEPTOR depletion in 3T3-L1 cells was
associated with a significant reduction in the transactivation
capability of PPAR-g (Figure 6E). Interestingly, the inclusion of
the potent PPAR-g agonist rosiglitazone corrected adipogenesis
and PPAR-g expression in cells with suppressed DEPTOR levels
(Figure 6F and Figure S6J). Together, these results indicate that
DEPTOR controls adipogenesis by regulating the activation of
the proadipogenic factors Akt/PKB and PPAR-g. We propose
a model in which the induction of DEPTOR during adipogenesis
functions to reduce the feedback loop from mTORC1 to IRS1,
which facilitates adipogenesis by upregulating the action of
Akt/PKB and PPAR-g.
DISCUSSION
Obesity increases mortality and the risk of developing multiple
disorders, including insulin resistance, type 2 diabetes, cardio-
vascular diseases, and cancers (Flegal et al., 2003, 2007; Pi-
schon et al., 2008; Wang et al., 2005). Here, we provide evidence
that DEPTOR plays a role in regulating fat accumulation in vivo
and in vitro. Observations made in two independent mouse
models, in humans, and in cultured cells all indicate that
DEPTOR expression positively associates with adiposity. These
results establish DEPTOR as a new physiological regulator of
adipogenesis.
The Fat and Lean mouse lines were previously selected based
on their fat content from a genetically highly variable base pop-
ulation formore than 60 generations (Sharp et al., 1984), resulting
in lines that differ in body fat content by more than 5-fold. The
low-resolution mapping initially detected the obesity QTL Fob3
in a region on chromosome 15 (Horvat et al., 2000). Follow-up
crosses of congenic line containing a large segment of chromo-
some 15 from the Lean line on otherwise Fat line background
provided a medium-resolution genetic map and revealed that
Deptor is located within the QTL (Stylianou et al., 2005). We
provide a detailed fine genetic mapping with congenic strains
carrying overlapping shorter Fob3a donor genomic segments
that further narrowed down Fob3a candidate interval to below
15 Mbp. Expression and bioinformatics analyses confirmed
thatDeptor is a high-priority candidate gene for fat accumulation
in this unique model of the common polygenic form of obesity.
Using a doxycycline-inducible mouse model, we observed
that overexpression of Deptor promotes adiposity in vivo, thus
confirming the analysesmade in the congenicmouse lines. Inter-
estingly, unlike the Fat-line-Deptor congenic mice that gain
significantly more weight than the lines carrying Lean-lineDeptor
allele on a regular diet, iDeptor mice need a higher lipid flux to
reproduce this phenotype. The exact reason for this phenom-
enon is unknown but may be related to differences in DEPTORCelexpression profile (duration and expression levels) or differences
in the genetic background of these models. Nevertheless, these
results indicate that DEPTOR overexpression promotes WAT
expansion in mice.
In iDeptor mice, increased DEPTOR expression promotes
the transcription of many genes regulated by PPAR-g that
favors lipid synthesis and uptake/esterification in WAT.
Consistent with these results, we observed that DEPTOR
modulates PPAR-g activity and the expression of many lipo-
genic genes in vitro. The fact that DEPTOR cell-autonomously
promotes adipogenesis in cultured cells strongly suggests that
DEPTOR may play a direct role in promoting WAT expansion.
In vitro, we noticed that DEPTOR expression triggers fat cell
development by promoting preadipocyte commitment as well
as lipid synthesis in committed cells. The increase in preadipo-
cyte differentiation coupled to the increase in lipid synthesis in
already committed cells may explain why we did not observe
a major change in average adipocyte size in WAT of iDeptor
mice.
The fact that DEPTOR expression is induced during adipocyte
differentiation raises the possibility that elevated DEPTOR levels
observed in WAT of the fat congenic mouse lines and in obese
humans could be a consequence rather than a cause of the
increased in adipogenesis. Although we cannot rule out the
contribution of adipogenesis per se to the increase in DEPTOR
levels in WAT of obese, a few facts indicate that adipogenesis
may not be the only factor contributing to promote DEPTOR
expression in obese. In the congenic mouse lines, elevated
DEPTOR expression was observed not only in WAT but also in
the liver of the obese congenic lines, indicating that high
DEPTOR expression in WAT is unlikely to be a consequence of
increased adipogenesis. Supporting this observation, prelimi-
nary analysis of the Deptor promoter revealed the presence of
many polymorphisms between the Fat and the Lean lines that
could contribute to the variation in Deptor expression levels
between these lines (data not shown). Finally, in WAT of obese
humans, we observed that the expression of the classic adipo-
genic marker aP2 was increased to a much lower extent than
DEPTOR, suggesting that the process of adipogenesis is unlikely
to be the only factor driving DEPTOR expression.
What promotes DEPTOR expression in WAT of humans is an
interesting question. To our knowledge, the Deptor locus has
not been linked to human obesity in any genome-wide associa-
tion studies published so far. Although we do not exclude the
possibility that polymorphisms in DEPTOR locus or in other
elements regulating DEPTOR expression/stability may be found
in obese humans, the striking elevation in DEPTOR levels
observed here among a population of unrelated individuals
suggests that a common mechanism taking place in WAT of
obese could promote DEPTOR expression. Interestingly, we
show that DEPTOR is highly induced by glucocorticoids, steroid
hormones that are secreted by the adrenal cortex in response to
stress (Morton, 2010). Excess of glucocorticoids, as seen in
Cushing’s syndrome or in humans chronically treated with exog-
enous glucocorticoids, causes many adverse effects, including
obesity (Stanbury and Graham, 1998). Many reports indicate
that the local conversion/activation of glucocorticoids is in-
creased inWAT of obese humans (Morton, 2010). In this context,
it is tempting to speculate that the increase in the locall Metabolism 16, 202–212, August 8, 2012 ª2012 Elsevier Inc. 207
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Figure 4. DEPTOR Expression Is Induced during Adipogenesis through a Transcriptional Mechanism Dependent on the Glucocorticoid
Receptor
(A) Subcutaneous adipose tissue frommouse embryos and pups at various stages of development were collected and stained with lipidTOX deep (neutral lipids/
red), isolectin GS IB4 (endothelial cells/green), and Hoechst (nucleus/blue) and then analyzed by microscopy. Representative pictures are shown for each
developmental stage. Protein lysates were prepared from tissues and analyzed by immunoblotting for indicated proteins.
(B and C) (B) MEFs or (C) 3T3-L1 were grown to confluence, and differentiation was induced in postconfluent cells (2 days) in the presence of the adipogenic
cocktail (insulin, IBMX, dexamethasone [and rosiglitazone in the case of MEFs] [see the Experimental Procedures]) for 2 days. The medium was replaced by
a medium containing serum and insulin for the rest of the differentiation process. Protein lysates were analyzed by immunoblotting for indicated proteins.
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DEPTOR Regulates Adipogenesisconversion of glucocorticoids in WAT of obese humans may
contribute to increase DEPTOR expression, which in turn could
facilitate WAT expansion by promoting its ability to store lipids.
The increase in fat accumulation observed in response to DEP-
TOR overexpression in the iDeptor mouse and in iDeptor MEFs
in vitro supports this possibility.
The positive role of DEPTOR in regulating adipogenesis, lipo-
genesis, and fat accumulation is counterintuitive, considering
that DEPTOR was reported to inhibit mTORC1 (Peterson et al.,
2009), a protein complex known to promote adipogenesis and
adipose cell maintenance (Cho et al., 2004; Gagnon et al.,
2001; Kim and Chen, 2004; Polak et al., 2008; Yu et al., 2008;
Zhang et al., 2009). We showed in the first DEPTOR report
that this protein inhibits S6K1 activation, which reduces the
negative feedback loop on IRS1/PI3K and promotes Akt/PKB
activity (Peterson et al., 2009). Here, we confirm that DEPTOR
promotes Akt/PKB action but, unexpectedly, found that this
was not associated with severe inhibition of the classical down-
stream effectors of mTORC1 (S6K1/S6, 4E-BP1), which have
been implicated in the regulation of adipogenesis downstream
of mTORC1 (Carnevalli et al., 2010; Le Bacquer et al., 2007).
Instead, we observed that DEPTOR reduces the phosphorylation
of IRS1 on S636/639, a site directly targeted by mTORC1 that
promotes IRS1 degradation (Tzatsos, 2009; Tzatsos and Kan-
dror, 2006). These results indicate that DEPTOR selectively
relieves the negative feedback loop on IRS1, which promotes
the action of the proadipogenic Akt/PKB, while preserving
the function of mTORC1 toward other substrates. From that
perspective, it is clear that DEPTOR does not block mTORC1
to nearly the same degree as rapamycin or RAPTOR loss, which
have both been shown to block adipogenesis. The incomplete
inhibition of mTORC1 action probably explains why DEPTOR
does not block adipogenesis. How DEPTOR selectively regu-
lates IRS1 without impairing S6K1/S6 or 4E-BP1 is unclear. It
is possible that chronic modulation of DEPTOR expression could
rewire the mTOR signaling pathway by modulating the relation
between mTORC1 and the numerous feedback loops (Laplante
and Sabatini, 2012). Such reorganization in the pathway could
lead to a new signaling equilibrium in which the elevation in
Akt/PKB could reactivate the action of mTORC1 toward some
substrates.
To dissect the respective contribution of mTORC1 and Akt/
PKB in the control of adipogenesis, Zhang et al. used Tuberous
sclerosis 2 (Tsc2) null MEFs (Zhang et al., 2009). Loss of TSC2
activates mTORC1 and, through mTORC1-dependent feed-(D) MEFs were differentiated for 4 days as described, but components of the adipo
were analyzed by immunoblotting for indicated proteins.
(E and F) MEFs were seeded at equal density and grown in the presence of var
analyzed by immunoblotting for indicated proteins, and (F) DeptormRNA was me
as the mean ± SEM for n = 4 per condition. *p < 0.05 versus control.
(G) MEFs were seeded at equal density and grown in the presence of various dose
for indicated proteins.
(H) MEFs were treated with dexamethasone (0.1 mM), cycloheximide (10 mg/ml),
Deptor RNA expression were quantified and analyzed as described in (E) and (F
(I) Promoter sequenceswere analyzed for the presence of glucocorticoid response
the optimal and the consensus GRE). Letters in red refer to nucleotides that are
(J) MEFs were treated with dexamethasone (1 mM) or vehicle for 16 hr. ChIP assay
or IgGs (see the Supplemental Experimental Procedures). qPCR was performed
(36B4). Data are expressed as the mean of two experiments ± SEM (n = 3–6 per
Celback mechanism, completely inhibits Akt/PKB. Using this
model, Zhang et al. showed that adipogenesis is enhanced
when mTORC1 is constitutively activated. These results differ
from our findings by suggesting that adipogenesis depends
on high mTORC1 activation and that the mTORC1-dependent
negative feedback loop on PI3K-Akt/PKB axis is not playing
a significant inhibitory role on this process. Importantly, the
supraphysiological activation of mTORC1 creates a signaling
context that might override regulatory processes that normally
take place during adipogenesis. For instance, basal PPAR-g
expression is induced by more than 30-fold in Tsc2 null cells
(Zhang et al., 2009). Overexpression of PPAR-g is sufficient
to induce adipogenesis and can partially correct the adipogenic
defect caused by the loss of Akt/PKB (Peng et al., 2003;
Tontonoz et al., 1994; Yun et al., 2009). The difference in
PPAR-g expression levels likely account for the different
results observed between the present study and the one from
Zhang et al.
DEPTOR overexpression increased glucose uptake, lipogen-
esis, and PPAR-g activation, which all represent key Akt/PKB-
controlled processes contributing to adipogenesis. Interestingly,
examples of proteins affecting adipogenesis through the modu-
lation of Akt/PKB and PPAR-g exist in the literature. The Tribbles
homolog 2 (TRB2) and TRB3 are pseudokinases acting as domi-
nant-negative regulators of several kinases, including Akt/PKB
(Du et al., 2003). TRB2/3 expression is reduced during adipogen-
esis, and their overexpression blocks Akt/PKB and PPAR-g acti-
vation and adipogenesis (Bezy et al., 2007; Naiki et al., 2007; Ta-
kahashi et al., 2008). The coordinated increase in DEPTOR levels
and the decrease in TRB2/3 during adipogenesis indicate that
preadipocytes trigger various signaling events to insure high
activation of proadipogenic signals.
In conclusion, we show that DEPTOR cell-autonomously pro-
motes adipogenesis and that elevated expression of DEPTOR
associates with obesity in mice and humans. These findings
improve our understanding of the molecular mechanisms regu-
lating WAT formation and may ultimately contribute to the devel-
opment of new tools to treat obesity and its related diseases.EXPERIMENTAL PROCEDURES
Antibodies and Cell Lines
Antibodieswere obtained from the following sources: antibody toDEPTOR (09-
463) from Upstate/Millipore; antibodies to phospho-S473 Akt/PKB(4058),
phospho-T308-Akt/PKB (2965), Akt/PKB (4691), ap2 (2120), C/EBP-a (2295),genic cocktail were removed as indicated (from day 0 to day 2). Protein lysates
ious doses of dexamethasone for the indicated time, (E) protein lysates were
asured by qRT-PCR and normalized to 36B4mRNA levels. Data are expressed
s of corticosterone for 24 hr. Protein lysates were analyzed by immunoblotting
actinomycin D (2.5 mg/ml), or RU486 (10 mM) for 10 hr. DEPTOR protein and
).
elements (GREs). Letters in green refer to conserved nucleotides (compared to
not conserved. N, any nucleotide; R, purine; Y, pyrimidine.
s were performed using an antibody raised against the glucocorticoid receptor
on various sections of Deptor promoter and in the promoter of a control gene
condition). *p < 0.05 versus control.
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Figure 5. DEPTOR Regulates Adipogenesis in a Cell-Autonomous Fashion
(A–C)MEFs isolated from iDeptormice were plated and grown to confluence. When confluent (day2), doxycycline (100 ng/ml) was added or not to the cells until
the end of the experiment. Two days after confluence (day 0), differentiation was induced using insulin, IBMX, dexamethasone, and rosiglitazone (see the
Experimental Procedures) for 2 days. The medium was replaced by a medium containing serum and insulin for the rest of the differentiation process. (A)
Triglycerides were extracted over the course of differentiation and then quantified. Data are expressed as mean ± SEM for n = 2–3 per condition. The experiment
was repeated using another iDeptor MEF line. *p < 0.05 versus control. A representative picture of MEFs 12 days after the initiation of differentiation is shown. (B
and C) mRNA expression of adipogenic genes was measured by qRT-PCR and normalized to 36B4 mRNA levels. Data are expressed as the mean ± SEM for
n = 3–6 per condition. *p < 0.05 versus control.
(D) DEPTOR induces the commitment of preadipocyte to adipocyte. iDeptor MEFs were grown to confluence, and adipocyte differentiation was induced as
described in (A). iDeptor MEFs were treated or not with doxycycline (100 ng/ml) from day2 to day 2 of the adipogenic protocol. Cells were then washed, and the
differentiation was completed without doxycycline. Triglycerides were extracted over the course of differentiation and then quantified. Data are expressed as
mean ± SEM for n = 5–6 per condition. *p < 0.05 versus control.
(E) DEPTOR induces lipogenesis in already committed cells. iDeptor MEFs were grown to confluence, and adipocyte differentiation was induced exactly as
described in (A). Differentiating cells were treated or not with doxycycline (100 ng/ml) from day 4 to day 16 of the adipogenic protocol, and triglycerides were
extracted. Data are expressed as the mean of three independent experiments ± SEM for n = 5–6 per condition. *p < 0.05 versus control.
(F–I) 3T3-L1 cells were infected with control or Deptor shRNA lentivirus. After selection with puromycine, cells were differentiated using the classical adipogenic
protocol. (F) Triglycerides were extracted over the course of differentiation and then quantified. Data are expressed as themean ± SEM for n = 6 per condition. *p <
0.05 versus control. A representative picture of 3T3-L1 cells 8 days after the initiation of differentiation. (G) Protein lysates were prepared at the indicated days and
analyzed by immunoblotting for indicated proteins. (H and I) mRNA expression of adipogenic genes was measured 4 days after the initiation of adipogenesis by
qRT-PCR and normalized to 36B4mRNA levels. Data are expressed as themean of two independent experiments ± SEM for n = 4 per condition. *p < 0.05 versus
control.
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DEPTOR Regulates AdipogenesisC/EBP-d (2318), PPAR-g (2443), mTOR (2983), Rictor (2140), Raptor (2280),
phospho-S636/639-IRS1 (2388), IRS1 (2382), 4E-BP1 (9452), phospho-T37/
46-4E-BP1 (2855), S6K1 (9202), phospho-T389 S6K1 (9205), S6 (2212), phos-
pho-S240/24-S6 (2215), NDRG1 (5196), phospho-T346-NDRG1 (3317), phos-
pho-PKCab-T636/641 (9375), FoxO1 (9462), phospho-T24 FoxO1/3a (9464),
and PTEN (9559), from Cell Signaling Technology; antibodies to C/EBP-b
(sc-150), Actin (sc-1616), PKCa (SC-208), GR (SC-1004), IgGs (sc-2027), and
Lamin A/C (sc-6215) from Santa Cruz Biotechnology. Secondary antibodies
were all purchased from Santa Cruz Biotechnology. 3T3-L1 cells were
purchased from ATCC and cultured as indicated. Primary mouse fibroblasts
were established from E13.5 embryos.
Differentiation of MEFs and 3T3-L1 into Adipocytes
For MEF differentiation, at 2 days postconfluence (day 0), cells were treated
with the adipogenic cocktail containing containing DMEM, FBS (10%), in-
sulin (830 nM), dexamethasone (1 mM), 3-isobutyl-1-methylxanthine (IBMX,
0.5 mM), and rosiglitazone (5 mM). Two days later, cells were switched to main-210 Cell Metabolism 16, 202–212, August 8, 2012 ª2012 Elsevier Inctenance medium containing DMEM, 10% FBS, and 830 nM insulin for the re-
maining duration of differentiation. The maintenance medium was changed
every 48 hr. 3T3-L1 cells were differentiated the same way, but rosiglitazone
was not included in the adipogenic cocktail.
Analysis of Adipose Tissue Development In Vivo
C57BL6/J females mice were mated with C57BL6/J males, and plugs
were checked to identify potential pregnant mice. Embryos were collected
18.5 days postimpregantion (E18.5), and pups were sacrificed 2, 5, and
12 days after birth. Subcutaneous adipose tissue was collected from the
inguinal region using microdissection tools, and samples were frozen in liquid
nitrogen for later analysis (western blotting and qRT-PCR) or directly used for
imaging. Small pieces of tissue were incubated in PBS containing Hoechst
(1:1000) (33342, Invitrogen), HCS LipidTOX (1:2000) (Invitrogen, H34476),
and isolectin GS-IB4M (1:5000) (I21411, Invitrogen) for 20 min. Tissues
were then washed twice with PBS, mounted, and analyzed by confocal
microscopy..
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Figure 6. DEPTORModulates Adipogenesis
by Regulating Akt/PKB and PPAR-g Activa-
tion
(A) MEFs isolated from iDeptor mice were plated
and grown to confluence. When confluent (day
2), cells were treated with the indicated doses of
doxycycline and differentiated using media sup-
plemented with insulin, IBMX, dexamethasone,
and rosiglitazone (day 0 to day 2) and with media
supplemented with insulin only (day 2 to day 8).
Protein lysates were prepared as described above
and analyzed by immunoblotting for indicated
proteins.
(B) Control and DEPTOR knockdown 3T3-L1
produced as described in Figure 5F were seeded
at equal density, grown to confluence, and lysed.
Protein lysates were analyzed by immunoblotting
for indicated proteins.
(C) Confluent iDeptor MEFs were treated or not
with doxycycline (100 ng/ml) for 2 days. Confluent
shCtrl or shDeptor_1 3T3-L1 cells were plated and
used when confluent. Cells were treated with
insulin (MEFs) or 10% serum (3T3-L1) and incu-
bated in the presence of 3H-2 deoxy-D-glucose
(2DG). Cells were then lysed, and radioactivity was
measured and corrected to protein content.
Results are expressed as the mean ± SEM for n =
4–6 per condition. *p < 0.05 versus control.
(D) Control and DEPTOR knockdown 3T3-L1 cells
were infected with pBABE-MyR-Akt or pBABE-
empty lentiviruses and were differentiated for 7 days. Results are expressed as the mean ± SEM for n = 6 per condition. *p < 0.05 versus control.
(E) Luciferase assay measuring the transactivation potential of PPAR-g toward a reporter containing several peroxisome proliferators response elements (PPRE)
transfected in 3T3-L1 cells with suppressed expression of Deptor by shRNA. Data are expressed as mean ± SEM for n = 6–8 per condition. This experiment was
repeated four times. *p < 0.05 versus control.
(F) Control and DEPTOR knockdown 3T3-L1 cells were differentiated with or without rosiglitazone (5 mM) for 8 days, and triglycerides were extracted and
quantified. Data are expressed as mean ± SEM for n = 3–5 per condition. *p < 0.05 versus control.
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The mean values for biochemical data from each group were compared by
Student’s t test where p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.cmet.2012.07.008.
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